Amylyx Pharmaceuticals (NASDAQ: AMLX)
Key Data Points
Amylyx Pharmaceuticals Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Amylyx Pharmaceuticals Company Info
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
News & Analysis
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.
3 Under-the-Radar Biotech Stocks to Buy in 2023
These three lesser-known biotech companies are profitable and growing revenue.
2 Incredible Growth Stocks Near 52-Week Lows to Buy Now
These two high-tech bio companies may be too cheap to ignore right now.
Why Shares of Amylyx Pharmaceuticals Were Up Monday
The company got a bump from an analyst's upgrade.
Better Growth Stock: Amylyx Pharmaceuticals or Viking Therapeutics?
Which of these red-hot biotech stocks is the better buy right now?
2 Supercharged Growth Stocks to Buy Right Now
These two biopharma stocks might be poised for a major breakout.
Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today
The biopharma's new ALS drug is exceeding projections on the sales front.
3 IPO Stocks That You Want to Own
This down market is giving us some really intriguing stocks at cheap prices
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.